TMEM263

Across TCGA pan-cancer cohorts, TMEM263 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM263 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM263 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM263 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where TMEM263 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.371	0.942	<.001	26	view →
CCRCC	DFS	Median	II,III,IV	0.474	0.756	.013	9	view →
UCEC	DFS	Quartile	All	1.000	0.783	.012	8	view →
LSCC	DFS	Tertile	II,III,IV	0.584	0.950	.005	8	view →
LUAD	DFS	Median	All	0.412	0.720	.015	3	view →
GBM	DFS	Median	All	0.487	0.247	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM263–PDAC (DFS)

Open the PDAC breakdown →